VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses. Issue 10 (13th August 2021)

• Record Type: Journal Article
• Authors: Wu, Chenyang; Cao, Xin; Zhang, Xiaojin
• Is Part Of: RSC medicinal chemistry. Volume 12:Issue 10(2021)
• Page Start: 1672
• Page End: 1679
• Publication Date: 2021-08-13
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1039/d1md00185j
• Languages: English
• ISSNs: 2632-8682

Abstract

Abstract : This review reports the function of VISTA in modulating immune response, and recent advances in VISTA inhibitor development. Abstract : V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is a novel negative checkpoint regulator that mediates T cell proliferation and cytokine production. The VISTA signaling pathway blockade has been proved as a promising strategy for cancer immunotherapy. Recent VISTA sequence analysis and crystal structure investigations have revealed its independent and unique function as compared with B7 family members, such as PD-1. This review will discuss VISTA binding partners and compare the structural differences between VISTA and other B7 family members, focusing on VISTA functions in immune activation and maintaining T cell quiescence. Recent progress and the therapeutic potential of biomacromolecules, such as monoclonal antibodies (mAbs) and small molecules targeting VISTA, are also discussed. Among these, a first-in-class small-molecule antagonist, CA-170, is highlighted.